Join the debate on indication-based pricing for cancer drugs in Europe. Is indication-based pricing still considered controversial or has the conversation moved on from “will this model work” to “how do we now implement this”?
Join this webinar to learn:
- What are the drivers for new value-based payment models such as indication-based pricing (IBP), particularly in Oncology?
- What is the impact of IBP on industry, payers, and patients; who are the winners and losers?
- How is IBP being implemented globally?
- What are the barriers to implementing IBP and how do we overcome them?